Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 0.54 |
| ▸ | DRD4 | P21917 | 13/20 | 0.54 |
| ▸ | DRD3 | P35462 | 10/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4776890 | 0.84 | HTR1A (0.56) | HTR1AALDH1A1GAA | |
| SCHEMBL4725722 | 0.83 | HTR1A (0.56) | HTR1AALDH1A1GAA | |
| SCHEMBL4776817 | 0.83 | HTR1A (0.56) | HTR1AALDH1A1GAA | |
| SCHEMBL5768086 | 0.82 | HTR1A (0.58) | HTR1AMEN1KMT2A | |
| SCHEMBL4729790 | 0.75 | ALDH1A1 (0.46) | ALDH1A1GAAMEN1TSHRKMT2A | |
| SCHEMBL11896615 | 0.73 | DRD4 (1.00) | DRD2DRD4DRD3GAA | |
| SCHEMBL5745448 | 0.73 | GAA (0.43) | ALDH1A1GAAMEN1TSHRKMT2A | |
| SCHEMBL8499789 | 0.73 | GSK3A (0.70) | ALDH1A1MEN1TSHRKMT2AGSK3A | |
| Hydrochloric Acid SCHEMBL8055377 | 0.72 | DRD4 (0.96) | DRD2DRD4DRD3GAA | |
| SCHEMBL10476759 | 0.72 | DRD4 (0.95) | DRD2DRD4DRD3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200470-A1 | Diaza- or Thiazadione Derivatives With Neuroprotective Activity | SCHWARTZ PHARMA S.L | 2008-08-21 | — | — | US | claimed |
| US-7351732-B2 | Cycloalkanedione derivatives, method for the production thereof and their pharmacological applications | SCHWARZ PHARMA S.L. (DE) | 2008-04-01 | — | — | US | claimed |
| EP-1711500-A1 | DIAZA- OR THIAZADIONE DERIVATIVES WITH NEUROPROTECTIVE ACTIVITY | Schwarz Pharma, s.l. (ES) | 2006-10-18 | — | — | EP | claimed |
| EP-1544201-B1 | NOVEL DERIVATIVES OF CYCLOALCANODIONES, METHOD FOR THE PRODUCTION THEREOF AND THEIR PHARMACOLOGICAL APPLICATIONS | CEPA SCHWARZ PHARMA S L (ES) | 2006-06-28 | — | — | EP | claimed |
| WO-2005075480-A1 | DIAZA- OR THIAZADIONE DERIVATIVES WITH NEUROPROTECTIVE ACTIVITY | SCHWARZ PHARMA S.L. (ES) | 2005-08-18 | — | — | WO | claimed |
| US-20080200470-A1 | Diaza- or Thiazadione Derivatives With Neuroprotective Activity | SCHWARTZ PHARMA S.L | 2008-08-21 | — | — | US | disclosed |
| US-7351732-B2 | Cycloalkanedione derivatives, method for the production thereof and their pharmacological applications | SCHWARZ PHARMA S.L. (DE) | 2008-04-01 | — | — | US | disclosed |
| EP-1711500-A1 | DIAZA- OR THIAZADIONE DERIVATIVES WITH NEUROPROTECTIVE ACTIVITY | Schwarz Pharma, s.l. (ES) | 2006-10-18 | — | — | EP | disclosed |
| EP-1544201-B1 | NOVEL DERIVATIVES OF CYCLOALCANODIONES, METHOD FOR THE PRODUCTION THEREOF AND THEIR PHARMACOLOGICAL APPLICATIONS | CEPA SCHWARZ PHARMA S L (ES) | 2006-06-28 | — | — | EP | disclosed |
| US-20050250777-A1 | Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications | SCHWARZ PHARMA S.L. (DE) | 2005-11-10 | — | — | US | disclosed |
| WO-2005075480-A1 | DIAZA- OR THIAZADIONE DERIVATIVES WITH NEUROPROTECTIVE ACTIVITY | SCHWARZ PHARMA S.L. (ES) | 2005-08-18 | — | — | WO | disclosed |
| EP-1544201-A1 | NOVEL DERIVATIVES OF CYCLOALCANODIONES, METHOD FOR THE PRODUCTION THEREOF AND THEIR PHARMACOLOGICAL APPLICATIONS | Cepa Schwarz Pharma s.l. (ES) | 2005-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250777-A1 | Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications | HTR3A, HTR1A, HTR5A | DRD2 93/4885DRD4 84/4885DRD3 92/4885 |
| US-20080200470-A1 | Diaza- or Thiazadione Derivatives With Neuroprotective Activity | HTR1A, HTR3A, HTR2A | DRD2 36/4885DRD4 52/4885DRD3 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.